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Background
Patients infected with hepatitis C virus (HCV) genotype 2 or 3 have sustained viro-
logic response rates of approximately 80% after receiving treatment with peginter-
feron and ribavirin for 24 weeks. We conducted a large, randomized, multinational, 
noninferiority trial to determine whether similar efficacy could be achieved with 
only 16 weeks of treatment with peginterferon alfa-2a and ribavirin.
Methods
We randomly assigned 1469 patients with HCV genotype 2 or 3 to receive 180 μg of 
peginterferon alfa-2a weekly, plus 800 mg of ribavirin daily, for either 16 or 24 weeks. 
A sustained virologic response was defined as an undetectable serum HCV RNA level 
(<50 IU per milliliter) 24 weeks after the end of treatment.
Results
The study failed to demonstrate that the 16-week regimen was noninferior to the 
24-week regimen. The sustained virologic response rate was significantly lower in 
patients treated for 16 weeks than in patients treated for 24 weeks (62% vs. 70%; 
odds ratio for 16 weeks vs. 24 weeks, 0.67; 95% confidence interval, 0.54 to 0.84; 
P<0.001). In addition, the rate of relapse (a detectable HCV RNA level during follow-up 
in patients who had undetectable HCV RNA at the end of treatment) was signifi-
cantly greater in the 16-week group (31%, vs. 18% in the 24-week group; P<0.001). 
The sustained virologic response rates in patients with a pretreatment serum HCV 
RNA level of 400,000 IU per milliliter or less was 82% with the 16-week regimen and 
81% with the 24-week regimen. Among patients with a rapid virologic response (an 
undetectable HCV RNA level by week 4), sustained virologic response rates were 
79% in the 16-week group and 85% in the 24-week group (P = 0.02).
Conclusions
Treatment with peginterferon and ribavirin for 16 weeks in patients infected with 
HCV genotype 2 or 3 results in a lower overall sustained virologic response rate 
than treatment with the standard 24-week regimen. (ClinicalTrials.gov number, 
NCT00077636.)
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The currently recommended treat-ment for patients infected with hepatitis C virus (HCV) genotype 2 or 3 is peginter-
feron, plus 800 mg of ribavirin daily, for 24 weeks.1 
Approximately 80% of patients have a sustained 
virologic response with this regimen.2,3 This high 
response rate has prompted studies of shorter 
treatment durations. Sustained virologic response 
rates of 80 to 85% were observed with just 12 to 
16 weeks of treatment in patients whose HCV 
RNA levels became undetectable within 4 weeks 
after commencing treatment.4-7 These results sug-
gest that patients with HCV genotype 2 or 3 who 
have a rapid virologic response (an undetectable 
HCV RNA level by week 4) could be treated for 
less than 24 weeks. However, confirmation is 
needed before a shortened treatment period can 
be widely recommended for patients with HCV 
genotype 2 or 3.8 In our large, randomized, multi-
national study, we aimed to determine whether 
similar efficacies could be achieved with 16 and 
24 weeks of treatment with peginterferon alfa-2a 
plus ribavirin in patients infected with HCV gen-
otype 2 or 3.
Me thods
The trial was designed by the sponsor and the 
principal academic investigators. The data were 
collected by Covance Central Laboratory Services 
and were managed by the sponsor and the aca-
demic investigators. The sponsor performed the 
statistical analysis. The academic investigators 
were responsible for the decision to publish the 
results and had unrestricted access to the data. 
An academic author wrote or edited all sections 
of the manuscript. One academic author (Dr. Shiff-
man) and one industry author (Ms. Lin) vouch for 
the completeness and accuracy of the data.
Selection of Patients
Eligible patients were those who were 18 years of 
age or older, were infected with HCV genotype 2 
or 3 (as determined with the use of the INNO-LiPA 
assay, Innogenetics), and had a quantifiable se-
rum HCV RNA level (>600 IU per milliliter), an 
elevated serum alanine transaminase level, and 
findings on liver biopsy consistent with chronic 
HCV infection. Patients were ineligible if they had 
other liver diseases, were infected with the hu-
man immunodeficiency virus, had hepatocellular 
carcinoma, had severe depression or another se-
vere psychiatric disease, had clinically significant 
cardiovascular or renal disease, had an uncon-
trolled seizure disorder, had severe retinopathy, 
or had previously received interferon or ribavirin. 
Patients with cirrhosis had to have a Child–Pugh 
score of less than 7 to be eligible.
Study Design
The study was conducted at 132 centers world-
wide. All sites received approval from an appropri-
ate institutional review board. The first patient 
was enrolled in November 2003, and the last pa-
tient completed follow-up in September 2005. Each 
patient provided written informed consent. Patients 
were randomly assigned, in a 1:1 ratio, to receive 
16 or 24 weeks of treatment with subcutaneous 
peginterferon alfa-2a (Pegasys, Roche), 180 μg 
once weekly, plus oral ribavirin (Copegus, Roche), 
400 mg twice daily. The treatment period was 
followed by a 24-week observation period. Patients 
were randomly assigned in blocks of four and 
were stratified according to HCV genotype and 
country of residence. Assignment to treatment 
duration was centralized, with the sponsor, investi-
gators, and patients unaware of the assignment. 
Treatment duration was double-blinded until week 
16, at which time investigators were informed by 
telephone of their patients’ assignments.
Efficacy Assessments
Serum HCV RNA levels were measured with the 
use of a qualitative polymerase-chain-reaction 
assay (Cobas Amplicor HCV Test, version 2.0; de-
tection limit, 50 IU per milliliter) at weeks 4, 12, 
and 16 or 24 during the treatment phase and at 
weeks 12 and 24 of follow-up. The primary end 
point was sustained virologic response, defined as 
an undetectable serum HCV RNA level at 24 weeks 
after the end of treatment. A rapid virologic re-
sponse was defined as an undetectable serum 
HCV RNA level by week 4 of treatment. Virologic 
relapse was defined as a detectable HCV RNA 
level during follow-up in patients who had had 
undetectable HCV RNA at the end of treatment.
Safety Assessments
Safety was assessed by means of physical exami-
nations and laboratory tests at weeks 2, 4, 8, 12, 
and 16 in both groups and at weeks 20 and 24 in 
the 24-week group (all during the treatment pe-
riod), as well as at weeks 4, 12, and 24 of the 
follow-up period in both groups. Stepwise reduc-
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1469 Were randomly assigned
to treatment
1810 Patients were screened
341 Were not randomly assigned because they
failed to meet inclusion criteria or were
 otherwise unwilling or unable to participate
1 Never took any study medication3 Never took any study medication
41 Were withdrawn
17 Had an adverse event
3 Had an abnormal lab-
oratory-test result
8 Refused treatment
3 Were withdrawn for
administrative or
other reasons
10 Were lost to follow-up
732 Were in the intention-
to-treat population
1 Was excluded because
original case report form
was unavailable
731 Were in the intention-
to-treat population
1 Was excluded because
original case report form
was unavailable
91 Were withdrawn
34 Had an adverse event
2 Had an abnormal lab-
oratory-test result
31 Refused treatment
2 Were withdrawn for
administrative or
other reasons
18 Were lost to follow-up
2 Violated an eligibility
criterion
2 Withdrew
736 Received 180 µg of peginterferon
 alfa-2a once weekly+800 mg
 of ribavirin daily for 16 wk
733 Received 180 µg of peginterferon
alfa-2a once weekly+800 mg
of ribavirin daily for 24 wk
733 (>99%) Received at least
one dose
732 (>99%) Received at least
one dose
715 (97%) Completed 8 wk
of treatment
714 (97%) Completed 8 wk
of treatment
692 (94%) Completed 16 wk
of treatment
685 (93%) Completed 16 wk
of treatment
641 (87%) Completed 24 wk
of treatment
690 (94%) Completed 12 wk
of follow-up
666 (91%) Completed 12 wk
of follow-up
667 (91%) Completed 24 wk
of follow-up
652 (89%) Completed 24 wk
of follow-up
AUTHOR:
FIGURE:
JOB: ISSUE:
4-C
H/T
RETAKE
SIZE
ICM
CASE
EMail Line
H/T
Combo
Revised
AUTHOR, PLEASE NOTE: 
Figure has been redrawn and type has been reset.
Please check carefully.
REG F
Enon
1st
2nd
3rd
Shiffman
1 of 5
07-12-07
ARTIST: ts
35702
Figure 1. Study Enrollment and Disposition of Patients.
Ten patients who never took medication, whose case report forms were unavailable, or who did not have safety assessments during the 
treatment period were excluded from the safety population.
The New England Journal of Medicine 
Downloaded from nejm.org at VIRGINIA COMMONWEALTH UNIV on January 15, 2015. For personal use only. No other uses without permission. 
 Copyright © 2007 Massachusetts Medical Society. All rights reserved. 
Treatment for 16 vs. 24 Weeks in Patients with HCV
n engl j med 357;2 www.nejm.org july 12, 2007 127
tions in the dose of peginterferon alfa-2a to 135 μg 
per week and then to 90 μg per week, and step-
wise reductions in the dose of ribavirin to 600 mg 
per day, were permitted, to manage clinically sig-
nificant adverse events or laboratory abnormali-
ties. Restoration of the initial doses was permitted 
at the discretion of the investigator if the adverse 
event or laboratory abnormality improved or re-
solved. Patients could receive peginterferon alfa-2a 
alone if ribavirin was stopped, but study treatment 
was discontinued if peginterferon alfa-2a was 
stopped. The use of granulocyte colony-stimulat-
ing factor and erythropoietin was permitted but 
not encouraged.
Table 1. Pretreatment Characteristics of the Patients.*
Characteristic 16 Wk of Peginterferon Alfa-2a + Ribavirin 24 Wk of Peginterferon Alfa-2a + Ribavirin
Genotype 2 
(N = 372)
Genotype 3 
(N = 358)
Any Genotype 
(N = 732)†
Genotype 2 
(N = 356)
Genotype 3 
(N = 369)
Any Genotype 
(N = 731)‡
Sex — no. (%)
Male 224 (60) 224 (63) 448 (61) 213 (60) 243 (66) 461 (63)
Female 148 (40) 134 (37) 284 (39) 143 (40) 126 (34) 270 (37)
Age — yr 49.5±9.2 42.4±9.0 46.0±9.8 49.3±9.3 42.1±9.4 45.6±10.0
Weight — kg 84.2±19.8 78.9±18.1 81.5±19.2 84.3±19.3 79.1±17.5 81.6±18.6
Body­mass index 28.7±5.8 26.8±5.5 27.8±5.7 28.7±5.8 26.6±5.1 27.6±5.6
Race or ethnic group — no. (%)
White 309 (83) 325 (91) 635 (87) 301 (85) 333 (90)  638 (87)
Black 12 (3) 10 (3) 22 (3) 18 (5) 3 (<1) 21 (3)
Asian 11 (3) 9 (3) 21 (3) 8 (2) 8 (2) 18 (2)
Other 40 (11) 14 (4) 54 (7) 29 (8) 25 (7) 54 (7)
Serum HCV RNA level
Mean ±SD — log IU/ml 6.38±0.85 6.15±0.88 6.27±0.87 6.40±0.87 6.15±0.80 6.27±0.85
≤400,000 IU/ml — no. (%) 63 (17) 97 (27) 160 (22) 55 (15) 91 (25) 147 (20)
>400,000–800,000 IU/ml — no. (%) 19 (5) 45 (13) 64 (9) 34 (10) 46 (12) 81 (11)
>800,000 IU/ml — no. (%) 290 (78) 216 (60) 508 (69) 267 (75) 232 (63)  503 (69)
Bridging fibrosis or cirrhosis — no. (%) 103 (28) 81 (23) 185 (25) 90 (25) 75 (20) 165 (23)
Steatosis — no. (%)
None 97 (26) 50 (14) 147 (20) 98 (28) 58 (16) 157 (21)
>0–5% of hepatocytes 101 (27) 90 (25) 191 (26) 94 (26) 85 (23) 181 (25)
6–33% of hepatocytes 30 (8) 58 (16) 88 (12) 22 (6) 66 (18) 89 (12)
34–66% of hepatocytes 11 (3) 41 (11) 53 (7) 13 (4) 39 (11) 52 (7)
>66% of hepatocytes 3 (<1) 10 (3) 13 (2) 0 4 (1) 4 (<1)
Unknown 130 (35) 109 (30) 240 (33) 129 (36) 117 (32) 248 (34)
* Plus–minus values are means ±SD. Data are from the intention­to­treat population (all patients who received at least one dose of study 
medication). The body­mass index is the weight in kilograms divided by the square of the height in meters. Race or ethnic group was self­
 reported. Liver biopsy was performed within 24 months before the start of the study, and specimens were assessed by local pathologists for 
histologic status and were reviewed by one central pathologist, who was unaware of group assignment, for steatosis. Pretreatment assess­
ments of liver steatosis were available for only approximately two thirds of patients. Steatosis was defined on the basis of the percentage of 
hepatocytes with fatty changes in one low­power field. The presence or absence of bridging fibrosis or cirrhosis could not be determined for 
one patient in the 24­week group.
† In addition to patients with HCV genotype 2 or 3 monoinfection, the overall group receiving treatment for 16 weeks included two patients 
infected with both HCV genotypes 2 and 4.
‡ In addition to patients with HCV genotype 2 or 3 monoinfection, the overall group receiving treatment for 24 weeks included four patients 
infected with both HCV genotypes 2 and 4, one with HCV genotype 1 only, and one with both HCV genotypes 1 and 2.
The New England Journal of Medicine 
Downloaded from nejm.org at VIRGINIA COMMONWEALTH UNIV on January 15, 2015. For personal use only. No other uses without permission. 
 Copyright © 2007 Massachusetts Medical Society. All rights reserved. 
Th e  n e w  e ng l a nd  j o u r na l  o f  m e dic i n e
n engl j med 357;2 www.nejm.org july 12, 2007128
Statistical Analysis
The primary analysis was based on data from the 
per-protocol population, according to guidelines 
of the International Conference on Harmonisa-
tion of Technical Requirements for Registration of 
Pharmaceuticals for Human Use, because it is 
considered to be more a conservative means of 
analysis in a noninferiority trial. A modified 
 intention-to-treat analysis was also performed, be-
cause it is considered to be a more stringent means 
of measuring overall efficacy and tolerability and 
it includes data from all patients who were ran-
domly assigned to a treatment group and who 
received at least one dose of study medication. 
Moreover, when intention-to-treat and per-proto-
col analyses lead to essentially the same conclu-
sions, confidence in the trial results is increased. 
Patients for whom HCV RNA levels had not been 
measured by the end of the follow-up period were 
considered to have had treatment failure.
Our primary objective was to show that treat-
ment for 16 weeks was no worse than treatment 
for 24 weeks, as defined by a noninferiority mar-
gin of 6%. Response rates at the end of the treat-
ment period and sustained virologic response 
rates in the two treatment groups were compared 
with the use of the Cochran–Mantel–Haenszel 
test (after data were stratified according to coun-
try of residence and HCV genotype). The common 
odds ratios and 95% confidence intervals were 
estimated. The interaction of treatment group 
and HCV genotype was assessed with the use of 
the Breslow–Day test, with data stratified accord-
ing to genotype. The noninferiority margin was 
converted from 6% to an odds ratio of 0.70 by 
assuming a sustained virologic response rate of 
80% in the 24-week group. On this basis, the 16-
week and 24-week regimens would be considered 
equivalent if the lower limit of the 95% confi-
dence interval for the odds ratio was at least 0.70. 
The planned enrollment of 700 patients per treat-
ment group assumed a sustained virologic re-
sponse rate of 80% in both groups, a statistical 
power of the study of 80%, and a two-sided sig-
nificance level of 0.05.
The safety analysis included data from all treat-
ed patients who underwent safety evaluations dur-
ing the treatment period. Stepwise, backward, 
and multiple logistic-regression analyses were 
used to examine the effect of treatment duration 
and pretreatment factors on the sustained viro-
logic response. There was evidence of an inter-
action between treatment group and genotype 
(P = 0.06), so separate analyses were performed 
according to genotype. The Cochran–Mantel–
Haenszel test was conducted on data stratified 
on the basis of country of residence. Data were 
not stratified for other subgroup analyses. P val-
ues were two-sided and were not adjusted for 
multiple testing.
R esult s
Of 1810 patients screened, 1469 were randomly 
assigned to a treatment group and 1465 received 
at least one dose of medication (Fig. 1). The two 
treatment groups were well matched (Table 1).
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Figure 2. Rates of Sustained Virologic Response in Patients Randomly 
 Assigned to Receive Treatment for 16 or 24 Weeks in the Per-Protocol 
 Analysis and the Modified Intention-to-Treat Analysis.
A sustained virologic response was defined as an undetectable serum  
HCV RNA level (<50 IU per milliliter) at 24 weeks after the end of treatment. 
In addition to patients who were withdrawn early, those who received less 
than 80% of the planned doses of either study drug were excluded from the 
per­protocol population. I bars indicate 95% confidence intervals.
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Virologic Response
The results failed to show noninferiority of the 
16-week regimen relative to the 24-week regimen in 
both the per-protocol and the modified intention-
to-treat analyses. Indeed, both analyses showed a 
similar pattern in the sustained virologic response 
rate among all patients, which was significantly 
lower in patients treated for 16 weeks than in 
those treated for 24 weeks in the per-protocol 
analysis (65% vs. 76%; odds ratio for 16 weeks 
vs. 24 weeks, 0.59; 95% confidence interval [CI], 
0.46 to 0.76; P<0.001) (Fig. 2A) and in the mod-
ified intention-to-treat analysis (62% vs. 70%; 
odds ratio, 0.67; 95% CI, 0.54 to 0.84; P<0.001) 
(Fig. 2B). All subsequent analyses were done on 
data from the modified intention-to-treat popu-
lation.
The virologic response rate at the end of the 
treatment period was significantly higher in the 
16-week group than in the 24-week group (odds 
ratio for 16 weeks vs. 24 weeks, 1.82; 95% CI, 1.35 
to 2.47), because more patients in the 24-week 
group were withdrawn prematurely and were con-
sidered not to have had a response. Thus, the sig-
nificant difference in the sustained virologic re-
sponse rate reflects a significantly higher relapse 
rate in the 16-week group (31%; 95% CI, 27 to 34) 
than in the 24-week group (18%; 95% CI, 15 to 
21; P<0.001) (Fig. 3).
Patients infected with HCV genotype 2 had 
higher virologic response rates at the end of treat-
ment and at the end of follow-up than did pa-
tients with HCV genotype 3 (Fig. 3). Within each 
genotype group, relapse rates were significantly 
higher among patients treated for 16 weeks than 
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Figure 3. Virologic Response Rates during the Treatment 
and Follow-up Periods in Patients Randomly Assigned 
to Receive Treatment for 16 or 24 Weeks. 
A rapid virologic response was defined as an undetect­
able serum HCV RNA level (<50 IU per milliliter) by 
week 4. An early virologic response was defined as an 
undetectable HCV RNA level, or a decrease in the HCV 
RNA level by more than 2 log10 units from the pretreat­
ment value, by week 12. A sustained virologic response 
was defined as an undetectable serum HCV RNA level 
at 24 weeks after the end of treatment. The overall data 
for sustained virologic response are given for patients 
infected with only HCV genotype 2 or 3 plus two pa­
tients with both HCV genotypes 2 and 4 in the 16­week 
group and four patients with both HCV genotypes 2 
and 4, one with HCV genotype 1 only, and one with 
both HCV genotypes 1 and 2 in the 24­week group.
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among those treated for 24 weeks (for genotype 2, 
30% vs. 15%; for genotype 3, 31% vs. 22%; P<0.001 
for both comparisons).
Predictors of Sustained Virologic Response
Prespecified stepwise, backward, and multiple 
logistic-regression analyses showed that several 
factors were predictive of sustained virologic re-
sponse: HCV genotype (odds ratio among patients 
with genotype 2 vs. genotype 3, 1.88; 95% CI, 
1.46 to 2.43; P<0.001); pretreatment HCV RNA 
level (odds ratio for ≤400,000 IU per milliliter vs. 
>800,000 IU per milliliter, 3.01; 95% CI, 2.15 to 
4.20; P<0.001; and odds ratio for >400,000 to 
800,000 IU per milliliter vs. >800,000 IU per mil-
liliter, 1.64; 95% CI, 1.10 to 2.46; P = 0.02); age 
(odds ratio for ≤45 years vs. >45 years, 1.50; 95% 
CI, 1.17 to 1.93; P = 0.002); weight (odds ratio for 
≤80 kg vs. >80 kg, 1.75; 95% CI, 1.37 to 2.24; 
P<0.001), alanine aminotransferase quotient (the 
patient’s alanine aminotransferase value divided 
by the upper limit of the normal range) (odds 
ratio for >3 vs. ≤3, 1.47; 95% CI, 1.14 to 1.90; 
P = 0.003); bridging fibrosis or cirrhosis (odds ratio 
for absence vs. presence, 2.15; 95% CI, 1.63 to 
2.81; P<0.001), and treatment duration (odds ratio 
for 24 weeks vs. 16 weeks, 1.56; 95% CI, 1.24 to 
1.97; P < 0.001).
Lower pretreatment HCV RNA level, lower 
weight, and absence of bridging fibrosis or cir-
rhosis were predictive of a sustained virologic 
response in separate analyses performed for pa-
tients with HCV genotype 2 and those with HCV 
genotype 3 (P<0.01 for all analyses). Treatment 
for 24 weeks predicted a sustained virologic 
response in patients infected with genotype 2 
(P<0.001) but not in those infected with geno-
type 3 (P = 0.12).
Subgroup Analyses
Subgroup analyses indicated that, with the possi-
ble exception of genotype, interactions between 
treatment duration and various factors were not 
significant (Fig. 4). The sustained virologic re-
sponse rate was higher in patients with HCV 
genotype 2 and those with HCV genotype 3 treat-
ed for 24 weeks than in corresponding patients 
treated for 16 weeks, but the difference was sig-
nificant only for patients with genotype 2.
A rapid virologic response was achieved in 67% 
of patients in the 16-week group and in 64% of 
patients in the 24-week group. Among the patients 
with a rapid virologic response, sustained viro-
logic response rates were consistently higher in 
the 24-week group than in the 16-week group, 
both overall (85% vs. 79%, P = 0.02) and within 
each genotype group (Fig. 5A). Sustained viro-
logic response rates were considerably lower among 
patients without a rapid virologic response than 
among those with a rapid response, and among 
those without a rapid response, sustained viro-
logic response rates were consistently higher in 
the 24-week group than in the 16-week group 
(Fig. 5B).
Safety
The most common cause of dose modifications 
of peginterferon alfa-2a and ribavirin were neu-
tropenia and anemia, respectively. The percentage 
of patients who had their dose of peginterferon 
alfa-2a reduced because of adverse events or labo-
ratory abnormalities was similar in the 24-week 
group and the 16-week group (17% and 14%, re-
spectively). In contrast, a higher percentage of 
patients in the 24-week group than in the 16-
week group had their dose of ribavirin reduced 
(23% vs. 17%, P = 0.01).
The percentage of patients reporting adverse 
events or serious adverse events was similar in the 
two groups. The adverse events reported were 
those typical of interferon-based treatment, in-
Figure 4 (facing page). Effect of Characteristics of Patients, 
before and during Treatment, on Sustained Virologic 
Response.
A sustained virologic response was defined as an un­
detectable serum HCV RNA level (<50 IU per milliliter) 
at 24 weeks after the end of treatment. Steatosis was 
defined as more than 5% of hepatocytes with fatty 
changes in one low­power field. A rapid virologic re­
sponse was defined as an undetectable serum HCV 
RNA level by week 4 of treatment. The shaded area in­
dicates odds ratios of at least 0.70, the noninferiority 
margin, showing that the 16­week group is at least as 
effective as the 24­week group. In addition to patients 
infected with HCV genotype 2 or 3, for the “all patients” 
and “any genotype” categories, the 16­week group in­
cluded two patients with HCV genotypes 2 and 4, and 
the 24­week group included four patients with HCV 
genotypes 2 and 4, one with HCV genotype 1, and one 
with HCV genotypes 1 and 2. Pretreatment assessments 
of liver steatosis were available for only approximately 
two thirds of patients. The presence or absence of cir­
rhosis or bridging fibrosis could not be determined for 
one patient in the 24­week group.
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cluding fatigue, headache, insomnia, and myalgia. 
Overall, 107 serious adverse events were report-
ed in 81 patients, with incidence in the 16-week 
group similar to that in the 24-week group (5% 
and 6%, respectively). Of these events, 29 were 
considered to be probably or possibly related to 
treatment. Grade 4 neutropenia was observed in 
13 patients (2%) treated for 16 weeks and in 20 
patients (3%) treated for 24 weeks. Severe anemia 
(defined as a hemoglobin level of <8.5 g per deci-
liter) developed in four patients (<1%) in each 
group. Nearly all patients (97% of those in the 
16-week group and 99% of those in the 24-week 
group) had at least one adverse event.
The percentage of patients withdrawn from the 
study during the first 16 weeks of therapy was 
similar in the two groups (Fig. 1). Overall, 4% of 
patients in the 16-week group and 5% of patients 
in the 24-week group were withdrawn because 
of adverse events or laboratory abnormalities.
Discussion
Our large, randomized study of patients infected 
with HCV genotype 2 or 3 shows that a fixed 16-
week regimen of peginterferon alfa-2a plus riba-
virin results in significantly lower sustained viro-
logic response rates than does a fixed 24-week 
regimen. Consistent with the overall result, the 
odds ratios for a sustained virologic response fa-
vored 24 weeks of treatment over 16 weeks in 
many subgroups, a finding that suggests that the 
preferred initial duration of treatment for patients 
with genotype 2 or 3 should continue to be 24 
weeks.
The results of several small studies suggest 
that treatment with pegylated interferon and riba-
virin for 12 or 16 weeks, rather than 24 weeks, 
does not adversely affect sustained virologic re-
sponse rates in patients with HCV genotype 2 or 
3.4-6 In two such studies,5,6 patients treated for 24 
weeks had somewhat lower virologic response 
rates at the end of the treatment period than did 
those receiving shorter regimens, presumably be-
cause of higher dropout rates with longer treat-
ment. In contrast, relapse rates were somewhat 
higher with the shorter duration of treatment. 
As a result, the higher dropout rates in the 24-
week treatment groups were offset by the higher 
relapse rates in the shorter-treatment groups, 
resulting in the groups having similar sustained 
virologic response rates. This finding led many 
to conclude that a shorter regimen is as effective 
as the standard 24-week regimen. The intention-
to-treat analysis of our data reveals the same 
pattern: higher dropout rates in the 24-week group 
and higher relapse rates in the 16-week group. 
Response rates at the end of the treatment pe-
riod were similar (within 3%; data not shown) in 
the two groups, according to the per-protocol 
analysis. This similarity, in addition to our large 
sample size, shows that reducing the treatment 
duration from 24 to 16 weeks results in increased 
relapse rates and therefore reduced sustained 
virologic response rates.
45
100
Su
st
ai
ne
d 
V
ir
ol
og
ic
 R
es
po
ns
e
(%
 o
f p
at
ie
nt
s)
80
90
70
60
40
30
10
50
20
0
Any HCV Genotype HCV Genotype 2 HCV Genotype 3
B Patients without a Rapid Virologic Response at Wk 4
A Patients with a Rapid Virologic Response at Wk 4
AUTHOR:
FIGURE:
JOB:
4-C
H/T
RETAKE
SIZE
ICM
CASE
EMail Line
H/T
Combo
Revised
AUTHOR, PLEASE NOTE: 
Figure has been redrawn and type has been reset.
Please check carefully.
REG F
Enon
1st
2nd
3rd
Shiffman
5 of 5
07-12-07
ARTIST: ts
35702 ISSUE:
22p3
16 Wk 24 Wk
100
Su
st
ai
ne
d 
V
ir
ol
og
ic
 R
es
po
ns
e
(%
 o
f p
at
ie
nt
s)
80
90
70
60
40
30
10
50
20
0
Any HCV Genotype HCV Genotype 2 HCV Genotype 3
16 Wk 24 Wk
85
80
85
78
85
79
26 26
53
26
39
Figure 5. Rates of Sustained Virologic Response among Patients  
with and Those without a Rapid Virologic Response.
A sustained virologic response was defined as an undetectable serum HCV RNA 
level (<50 IU per milliliter) at 24 weeks after the end of treatment. A rapid 
virologic response was defined as an undetectable serum HCV RNA level 
by week 4 of treatment. T bars indicate the upper bound of the 95% confi­
dence interval.
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The customization of the duration of therapy 
is an emerging theme in the management of 
chronic HCV.5,9-11 In patients infected with geno-
type 2 or 3, a variable treatment regimen (12 
weeks in patients with a rapid virologic response 
and 24 weeks in those without a rapid virologic 
response) resulted in a sustained virologic response 
rate (77%) similar to that from a standard 24-
week regimen (76%).5 Our study was not designed 
to evaluate this treatment approach, but our re-
sults shed light on its validity. Overall, 66% of 
patients with HCV genotype 2 or 3 had rapid vi-
rologic responses in our study, a figure similar 
to that found by Mangia et al. (63%).5 The sus-
tained virologic response rate among patients 
with a rapid virologic response treated for 16 
weeks and those without a rapid virologic re-
sponse treated for 24 weeks — a population sim-
ilar to the variable-duration group in the study 
by Mangia et al. — was 68%, similar to the 70% 
rate in our fixed 24-week group. A variable-dura-
tion treatment strategy may therefore be as effec-
tive as a fixed-duration strategy and may be less 
expensive for and better tolerated by the majority 
of patients. The trade-off in reducing the treat-
ment duration is an increased relapse rate, which 
was observed in our study and in other studies.4-6 
Thus, the reduction of the treatment duration, 
even in patients with rapid virologic responses, is 
likely to be accompanied by higher relapse rates 
and the need to consider retreatment for these 
patients.
Could higher doses of ribavirin prevent relapse 
after treatment for less than 24 weeks? In previ-
ous studies, treatment for 24 weeks with ribavirin 
(with the dose based on body weight) provided 
no benefit over the recommended ribavirin dose 
of 800 mg per day in patients infected with HCV 
genotype 2 or 3.2,12 In fact, one study13 has sug-
gested that it may be possible to reduce the riba-
virin dose to 400 mg per day without compro-
mising the efficacy of the standard 24-week 
regimen. Ribavirin doses as high as 1200 mg per 
day, which have been used in studies evaluating 
reduced durations of therapy,5-7 appear to offer 
no obvious benefit in reducing the relapse rate. 
However, further study is needed to confirm the 
optimal dose of ribavirin for abbreviated treat-
ment regimens.
Sustained virologic response rates decrease in 
inverse proportion to pretreatment viral load.2,3,14 
Among patients with a pretreatment viral load of 
400,000 IU per milliliter or less in our study, the 
sustained virologic response rate was 1% higher 
in the 16-week group than in the 24-week group. 
Among those with a pretreatment viral load of 
more than 400,000 IU per milliliter, the differ-
ence was 11%, in favor of the 24-week regimen. 
Patients with low pretreatment viral loads or rapid 
virologic responses have the highest likelihood 
(>78%) of a sustained virologic response with 16 
weeks of therapy. Reduced durations of therapy 
may also be reasonable in patients who have ad-
verse events and are unlikely to tolerate 24 weeks 
of therapy. The decision to reduce the duration of 
treatment must be balanced against the increased 
risk of relapse. Patients who do not have a rapid 
virologic response should not be considered easy 
to cure and should not be offered abbreviated 
treatment.
In conclusion, our study shows that a fixed 
16-week regimen is inferior to a fixed 24-week 
regimen in patients with HCV genotype 2 or 3. 
These patients should not be routinely treated for 
less than the currently recommended 24 weeks. 
However, patients with a low pretreatment viral 
load or a rapid virologic response appear to have 
the highest probability of having a sustained re-
sponse with 16 weeks of therapy, and such thera-
py may be a reasonable option for these patients.
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